Conclusions and implications
The nanoreactors containing GOx activity are fully suitable for
cytotoxicity generation in tumor cells. The HSA functionalization of the
VLP-GOx nanoreactors could result in a prevailing strategy to improve
selective cancer targeting. The GOx containing enzymatic nanoreactors
seems to be an interesting alternative to improve the current cancer
therapy. In vivo studies are ongoing to reinforce the
effectiveness of this treatment strategy.